Rep. Robert Bresnahan, Jr. Sells Off Shares of Agilent Technologies, Inc. (NYSE:A)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently sold shares of Agilent Technologies, Inc. (NYSE:A). In a filing disclosed on April 28th, the Representative disclosed that they had sold between $1,001 and $15,000 in Agilent Technologies stock on April 8th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of DexCom (NASDAQ:DXCM) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Invesco (NYSE:IVZ) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Generac (NYSE:GNRC) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Occidental Petroleum (NYSE:OXY) on 4/8/2025.
• Sold $15,001 – $50,000 in shares of Pfizer (NYSE:PFE) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of QUALCOMM (NASDAQ:QCOM) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Best Buy (NYSE:BBY) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of EOG Resources (NYSE:EOG) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of CSX (NASDAQ:CSX) on 4/8/2025.
• Sold $1,001 – $15,000 in shares of Valero Energy (NYSE:VLO) on 4/8/2025.

Agilent Technologies Price Performance

Shares of Agilent Technologies stock opened at $107.46 on Wednesday. The business’s 50-day moving average price is $115.21 and its 200-day moving average price is $130.50. The firm has a market capitalization of $30.64 billion, a PE ratio of 24.70, a price-to-earnings-growth ratio of 3.01 and a beta of 1.19. Agilent Technologies, Inc. has a 12 month low of $96.43 and a 12 month high of $155.35. The company has a current ratio of 2.20, a quick ratio of 1.66 and a debt-to-equity ratio of 0.56.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, February 26th. The medical research company reported $1.31 EPS for the quarter, beating analysts’ consensus estimates of $1.27 by $0.04. The business had revenue of $1.68 billion for the quarter, compared to analysts’ expectations of $1.67 billion. Agilent Technologies had a net margin of 19.27% and a return on equity of 25.56%. Sell-side analysts forecast that Agilent Technologies, Inc. will post 5.54 EPS for the current fiscal year.

Agilent Technologies Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st were paid a dividend of $0.248 per share. This represents a $0.99 annualized dividend and a yield of 0.92%. The ex-dividend date was Tuesday, April 1st. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.76%.

Institutional Investors Weigh In On Agilent Technologies

Several institutional investors and hedge funds have recently modified their holdings of the stock. CKW Financial Group raised its stake in Agilent Technologies by 114.9% in the fourth quarter. CKW Financial Group now owns 187 shares of the medical research company’s stock worth $25,000 after buying an additional 100 shares in the last quarter. Global X Japan Co. Ltd. raised its position in shares of Agilent Technologies by 161.1% in the 4th quarter. Global X Japan Co. Ltd. now owns 188 shares of the medical research company’s stock worth $25,000 after acquiring an additional 116 shares in the last quarter. Redwood Park Advisors LLC bought a new position in shares of Agilent Technologies in the 4th quarter worth approximately $27,000. Lee Danner & Bass Inc. bought a new stake in shares of Agilent Technologies during the fourth quarter valued at approximately $29,000. Finally, Whipplewood Advisors LLC grew its stake in Agilent Technologies by 286.2% in the first quarter. Whipplewood Advisors LLC now owns 251 shares of the medical research company’s stock worth $29,000 after purchasing an additional 186 shares during the period.

Insiders Place Their Bets

In other Agilent Technologies news, VP Rodney Gonsalves sold 1,908 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total transaction of $232,737.84. Following the completion of the transaction, the vice president now owns 21,786 shares of the company’s stock, valued at approximately $2,657,456.28. This trade represents a 8.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Daniel K. Podolsky sold 1,819 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $116.46, for a total value of $211,840.74. Following the completion of the sale, the director now directly owns 35,737 shares in the company, valued at approximately $4,161,931.02. This represents a 4.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. TD Cowen boosted their price target on shares of Agilent Technologies to $135.00 and gave the stock a “buy” rating in a research note on Thursday, April 10th. Wells Fargo & Company dropped their target price on Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating for the company in a report on Thursday, April 17th. Robert W. Baird decreased their price target on Agilent Technologies from $161.00 to $159.00 and set an “outperform” rating on the stock in a research note on Thursday, February 27th. Barclays dropped their price objective on Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating for the company in a research note on Thursday, April 10th. Finally, Jefferies Financial Group cut their target price on shares of Agilent Technologies from $135.00 to $116.00 and set a “hold” rating on the stock in a report on Monday, April 21st. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $143.00.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.